Predictors for development of oxaliplatin-induced peripheral neuropathy in cancer patients as determined by ordered logistic regression analysis
Abstract This retrospective study aimed to identify predictors for the development of oxaliplatin-induced peripheral neuropathy (OXAIPN). Between January 2017 and March 2021, a total 322 cancer patients at our hospital who were receiving oxaliplatin were enrolled. For the regression analysis of factors associated with oxaliplatin-induced peripheral neuropathy, variables were extracted manually from medical charts. The level of OXAIPN was evaluated using the National Cancer Institute’s Common Terminology Criteria for Adverse Events (version 5). Multivariate ordered logistic regression analysis was performed to identify predictors for the development of OXAIPN. Optimal cut-off thresholds were determined using receiver operating characteristic (ROC) analysis. Values of P < 0.05 (2-tailed) were considered significant. Significant factors identified included body mass index (BMI) (odds ratio [OR] = 1.06, 95% confidence interval [CI] = 1.00–1.12; P = 0.046), number of cycles (OR = 1.09, 95%CI = 1.05–1.14; P < 0.0001), S-1 plus oxaliplatin (SOX) regimen (OR = 0.54, 95%CI = 0.32–0.92; P = 0.023), concomitant use of proton pump inhibitors (PPIs) (OR = 1.64, 95%CI = 1.05–2.58; P = 0.031) and concomitant use of analgesic adjuvant (OR = 3.30, 95%CI = 1.09–9.97; P = 0.035). ROC analysis revealed that peripheral neuropathy (grade 2 or higher) was more likely to occur with ≥8 cycles, with 66.3% sensitivity and 56.5% specificity (area under the curve [AUC] = 0.65), and BMI ≥20.5 kg/m2, with 63.3% sensitivity and 47.8% specificity (AUC = 0.54). In conclusion, BMI, number of cycles, SOX regimen, concomitant use of PPIs and concomitant use of analgesic drugs were identified as significant predictors for the development of OXAIPN.